A cell-based high-throughput screen identifies drugs that cause bleeding disorders by off-targeting the vitamin K cycle
- 13 August 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 136 (7), 898-908
- https://doi.org/10.1182/blood.2019004234
Abstract
Drug-induced bleeding disorders contribute to substantial morbidity and mortality. Antithrombotic agents that cause unintended bleeding with obvious reasons are relatively easy to control. However, the mechanisms of most drug-induced bleeding disorders are poorly understood which makes intervention more difficult. As most bleeding disorders are associated with the dysfunction of coagulation factors, we adapted our recently established cell-based assay to identify drugs that impact the biosynthesis of active vitamin K-dependent (VKD) coagulation factors with possible off-target effects. The NIH Clinical Collection (NCC) library containing 727 drugs was screened and 9 drugs, including the most commonly prescribed anticoagulant warfarin, were identified. Bleeding complications associated with most of these drugs have been clinically reported, but the pathogenic mechanisms remain unclear. Further characterization of the 9 top-hit drugs on the inhibition of VKD carboxylation suggests that warfarin, lansoprazole, and nitazoxanide mainly target vitamin K epoxide reductase (VKOR), while idebenone, clofazimine, and AM404 mainly target vitamin K reductase (VKR) in vitamin K redox cycling. The other three drugs mainly affect vitamin K availability within the cells. The molecular mechanisms underlying the inactivation of VKOR and VKR by these drugs are clarified. Results from both cell-based and animal model studies suggest that the anticoagulation effect of drugs targeting VKOR, but not VKR, can be rescued by the administration of vitamin K. These findings provide insights into the prevention and management of drug-induced bleeding disorders. The established cell-based high-throughput screening approach provides a powerful tool for identifying new vitamin K antagonists that function as anticoagulants.Keywords
This publication has 77 references indexed in Scilit:
- Research Perspective: Potential Role of Nitazoxanide in Ovarian Cancer Treatment. Old Drug, New Purpose?Cancers, 2013
- Evaluation of warfarin resistance using transcription activator‐like effector nucleases‐mediated vitamin K epoxide reductase knockout HEK293 cellsJournal of Thrombosis and Haemostasis, 2013
- Adverse drug reactions in older patients: an Italian observational prospective hospital studyDrug, Healthcare and Patient Safety, 2012
- Vitamin K epoxide reductase contributes to protein disulfide formation and redox homeostasis within the endoplasmic reticulumMolecular Biology of the Cell, 2012
- NQO1-Dependent Redox Cycling of Idebenone: Effects on Cellular Redox Potential and Energy LevelsPLOS ONE, 2011
- Functional study of the vitamin K cycle in mammalian cellsBlood, 2011
- Reduction of Clofazimine by Mycobacterial Type 2 NADH:Quinone OxidoreductaseOnline Journal of Public Health Informatics, 2011
- Sex differences in thrombosis in mice are mediated by sex-specific growth hormone secretion patternsJCI Insight, 2008
- Which drugs cause preventable admissions to hospital? A systematic reviewBritish Journal of Clinical Pharmacology, 2006
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004